Placebo for ritonavir

DRUG4 trials

Sponsors

AbbVie, Abbott, Pfizer

Conditions

COVID-19HCV Infection

Phase 1

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

CompletedNCT00850044

AbbVieHCV Infection

Start: 2009-02-28Updated: 2017-11-20

Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

CompletedNCT00931281

AbbottHCV Infection

Start: 2009-06-30Updated: 2010-10-13

Phase 2

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

CompletedNCT05047601

Start: 2021-09-09End: 2022-04-12Updated: 2023-05-06

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

CompletedNCT05438602

Start: 2022-08-03End: 2023-11-13Updated: 2024-09-23

Related Papers

Health-related quality of life in immunocompromised adults with mild–moderate COVID-19 treated with nirmatrelvir-ritonavir: results from the randomized, double-blinded EPIC-IC trial

Health and Quality of Life Outcomes2026-03-19

Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial.

2025-10-14

Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial.

2025-07-146 citations

Integrated virologic analysis of resistance to nirmatrelvir/ritonavir in individuals across four phase 2/3 clinical studies for the treatment of COVID-19.

2025-06-30

Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19

New England Journal of Medicine2024-07-1723 citations

Clinical Trials of Respiratory Virus Infections: How to Address Challenges and Prepare for the Future

Infectious Diseases & Immunity2024-06-12

Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.

2016-02-2423 citations